

U.S. UTILITY Patent Application						PATENT NUMBER <i>end</i> ISSUE DATE
APPL. NUM 10026966	FILING DATE 12/19/2001	CLASS 261 602	SUBCLASS 25.2	GAU 1616	EXAMINER <i>Habte</i>	
<b>**APPLICANTS:</b> Bebbington David; Charrier Jean-Damien; <i>1609</i> <i>1624</i> <i>1626</i> <i>1624</i> <i>bis morpholine</i> <i>p.299</i>						
<b>**CONTINUING DATA VERIFIED:</b> THIS APPLN CLAIMS BENEFIT OF 60/257,887 12/21/2000 AND CLAIMS BENEFIT OF 60/286,949 04/27/2001						
<b>** FOREIGN APPLICATIONS VERIFIED:</b>						
<input type="checkbox"/> PG-PUB <input type="checkbox"/> DO NOT PUBLISH		<input type="checkbox"/> RESCIND		ATTORNEY-DOCKET NO <i>VPI/00-130-06</i>		
Foreign priority claimed <input type="checkbox"/> yes <input type="checkbox"/> no		35 USC 119 conditions met <input type="checkbox"/> yes <input type="checkbox"/> no				
Verified and Acknowledged Examiners's initials <i>[Signature]</i>						
<b>TITLE :</b> Pyrazole compounds useful as protein kinase inhibitors						
<small>U.S. DEPT. OF COMM./PAT. &amp; TM-PTO-436L (Rev. 12-94)</small>						

Notice of ALLOWANCE (cont'd.)		Assistant Examiner		Custodian	
RECEIVED		Primary Examiner		Applicant Examiner	
Amount Due	Due Date				
<input type="checkbox"/> TERMINAL <input type="checkbox"/> DISCLAIMER		PREPARED FOR ISSUE <small>WARNING: The information contained herein may be restricted. Unauthorized disclosure may be punishable by the U.S. Patent and Trademark Office under 35 U.S.C. Sections 122, 181 and 361, and 17 U.S.C. Sections 401-412. The U.S. Patent and Trademark Office is restricted to commercial applications and our use only.</small>		<small>CD-ROM</small> <small>www.uspto.gov</small>	

FILED WITH:

DISK (CD)

CD-ROM